The mechanism of DAB2IP in chemoresistance of prostate cancer cells

Clinical Cancer Research

Volumn 19, Issue 17, 2013, Pages 4740-4749

  Wu, Kaijie ^a,b   Xie, Daxing ^b   Zou, Yonglong ^b   Zhang, Tingting ^a,b   Pong, Rey Chen ^b   Xiao, Guanghua ^b   Fazli, Ladan ^c   Gleave, Martin ^c   He, Dalin ^a   Boothman, David A ^b,e   Hsieh, Jer Tsong ^b,d,e  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA CATENIN; CLUSTERIN; CUSTIRSEN; DOCETAXEL; EARLY GROWTH RESPONSE FACTOR 1; EPOTHILONE B; GEMCITABINE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; PROTEIN DAB2IP; ROMIDEPSIN; SHORT HAIRPIN RNA; SOMATOMEDIN C; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN C4 2; CHEMOSENSITIVITY; CLUSTERIN GENE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTERIN; DRUG RESISTANCE, NEOPLASM; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE, KNOCKOUT; PROSTATIC NEOPLASMS; RAS GTPASE-ACTIVATING PROTEINS; TAXOIDS; WNT SIGNALING PATHWAY;

EID: 84883476051     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0954     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45. (Pubitemid 33741879)
3. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8:12-23.
4. Galsky MD, Vogelzang NJ. Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 2010;21:2135-44.
5. Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, et al. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem 2002;277:12622-31. (Pubitemid 34952621)
6. Chen H, Karam JA, Schultz R, Zhang Z, Duncan C, Hsieh JT. Cloning of mouse Dab2ip gene, a novel member of the RasGTPase-activating protein family and characterization of its regulatory region in prostate. DNA Cell Biol 2006;25:232-45. (Pubitemid 43668285)
7. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005;280:22437-44. (Pubitemid 40827899)
8. Dote H, Toyooka S, Tsukuda K, Yano M, Ouchida M, Doihara H, et al. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res 2004;10:2082-9. (Pubitemid 38375570)
9. Dote H, Toyooka S, Tsukuda K, Yano M, Ota T, Murakami M, et al. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. Br J Cancer 2005;92:1117-25. (Pubitemid 40546678)
10. Yano M, Toyooka S, Tsukuda K, Dote H, Ouchida M, Hanabata T, et al. Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer 2005;113:59-66. (Pubitemid 39507311)
11. Qiu GH, Xie H, Wheelhouse N, Harrison D, Chen GG, Salto-Tellez M, et al. Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma. J Hepatol 2007;46:655-63. (Pubitemid 46420382)
12. Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007;99:1836-44. (Pubitemid 351767196)
13. Chen H, Toyooka S, Gazdar AF, Hsieh JT. Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem 2003;278:3121-30. (Pubitemid 36801222)
14. Wu K, Liu J, Tseng SF, Gore C, Ning Z, Sharifi N, et al. The role of DAB2IP in androgen receptor activation during prostate cancer progression. Oncogene 2013 Apr 22. [Epub ahead of print].
15. Xie D, Gore C, Zhou J, Pong RC, Zhang H, Yu L, et al. DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc Natl Acad Sci U S A 2009;106:19878-83.
16. Xie D, Gore C, Liu J, Pong RC, Mason R, Hao G, et al. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A 2010;107:2485-90.
17. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010;16:286-94.
18. Zhang H, He Y, Dai S, Xu Z, Luo Y, Wan T, et al. AIP1 functions as an endogenous inhibitor of VEGFR2-mediated signaling and inflammatory angiogenesis in mice. J Clin Invest 2008;118:3904-16.
19. Kong Z, Xie D, Boike T, Raghavan P, Burma S, Chen DJ, et al. Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation. Cancer Res 2010;70:2829-39.
20. Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 2008;102:389-97. (Pubitemid 352019195)
21. Criswell T, Beman M, Araki S, Leskov K, Cataldo E, Mayo LD, et al. Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J Biol Chem 2005;280:14212-21. (Pubitemid 40517323)
22. Thyss R, Virolle V, Imbert V, Peyron JF, Aberdam D, Virolle T. NF-kappaB/Egr-1/Gadd45 are sequentially activated upon UVB irradiation to mediate epidermal cell death. EMBO J 2005;24:128-37. (Pubitemid 40188470)
23. Mittanck DW, Kim SW, Rotwein P. Essential promoter elements are located within the 5′ untranslated region of human insulin-like growth factor-I exon I. Mol Cell Endocrinol 1997;126:153-63. (Pubitemid 27121053)
24. Goetz EM, Shankar B, Zou Y, Morales JC, Luo X, Araki S, et al. ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability. Oncogene 2011;30:3745-54.
25. Djeu JY, Wei S. Clusterin and chemoresistance. Adv Cancer Res 2009;105:77-92.
26. Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 2010;16:1088-93.
27. Jin G, Howe PH. Regulation of clusterin gene expression by transforming growth factor beta. J Biol Chem 1997;272:26620-6. (Pubitemid 27458885)
28. Tice DA, Soloviev I, Polakis P. Activation of the Wnt pathway interferes with serum response element-driven transcription of immediate early genes. J Biol Chem 2002;277:6118-23. (Pubitemid 34968399)
29. Reddy KB, Karode MC, Harmony AK, Howe PH. Interaction of transforming growth factor beta receptors with apolipoprotein J/clusterin. Biochemistry 1996;35:309-14. (Pubitemid 26036436)
30. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010;70:7992-8002.
31. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011;71:6019-29.
32. Moretti RM, Marelli MM, Mai S, Cariboni A, Scaltriti M, Bettuzzi S, et al. Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis. Cancer Res 2007;67:10325-33. (Pubitemid 350070807)
33. Trougakos IP, Djeu JY, Gonos ES, Boothman DA. Advances and challenges in basic and translational research on clusterin. Cancer Res 2009;69:403-6.
34. Michel D, Chatelain G, North S, Brun G. Stress-induced transcription of the clusterin/apoJ gene. Biochem J 1997;328 (Pt 1):45-50. (Pubitemid 27499438)
35. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000;60:170-6. (Pubitemid 30058748)
36. Patterson SG, Wei S, Chen X, Sallman DA, Gilvary DL, Zhong B, et al. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 2006;25:6113-22. (Pubitemid 44562409)
37. Zhong B, Sallman DA, Gilvary DL, Pernazza D, Sahakian E, Fritz D, et al. Induction of clusterin by AKT-role in cytoprotection against docetaxel in prostate tumor cells. Mol Cancer Ther 2010;9:1831-41.
38. Shiota M, Zoubeidi A, Kumano M, Beraldi E, Naito S, Nelson CC, et al. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer. Mol Cancer Res 2011;9:1755-66.
39. Gitenay D, Baron VT. Is EGR1 a potential target for prostate cancer therapy? Future Oncol 2009;5:993-1003.
40. Eid MA, Kumar MV, Iczkowski KA, Bostwick DG, Tindall DJ. Expression of early growth response genes in human prostate cancer. Cancer Res 1998;58:2461-8. (Pubitemid 28252710)
41. Wei L, Xue T, Wang J, Chen B, Lei Y, Huang Y, et al. Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer. Int J Cancer 2009;125:791-806.